-
公开(公告)号:US20190022005A1
公开(公告)日:2019-01-24
申请号:US16115973
申请日:2018-08-29
申请人: Henry J. Smith , James R. Smith
发明人: Henry J. Smith , James R. Smith
IPC分类号: A61K9/127
摘要: A process for treating tumors by administering a mixture of cancer fighting drugs incorporated into a stabilized liposomal formulation. Each cancer drug is selected to target a different phase of the cell-cycle of the cancer cell thus expanding the number of cancer cells that can be killed at one time without compromising the safety of the patient. The stabilized multi-drug liposomes are designed to extravasate thru “leaky” blood capillaries supplying the tumor and enter the tumor tissue where they will accumulate over time and ultimately release the mixture of cancer drugs to kill surrounding tumor cells. The multi-drug liposomes are likewise unable to extravasate thru normal blood capillaries and will thus be less toxic to normal tissues.
-
公开(公告)号:US20130039973A1
公开(公告)日:2013-02-14
申请号:US13566663
申请日:2012-08-03
申请人: Henry J. Smith , James R. Smith
发明人: Henry J. Smith , James R. Smith
IPC分类号: A61K39/00 , A61P31/16 , A61K39/145 , A61K9/127 , A61K39/39
CPC分类号: A61K9/127 , A61K9/0019 , A61K9/0073 , A61K9/1271 , A61K9/14 , A61K31/713 , A61K39/00 , A61K39/12 , A61K39/145 , A61K2039/545 , A61K2039/55505 , A61K2039/55555 , A61K2039/55561 , C12N7/00 , C12N2760/16134 , C12N2760/16171 , A61K2300/00
摘要: Disclosed herein are immunogenic compositions for producing immediate and sustained immunity to infectious viral and bacteriological pathogens. A univalent immunogenic composition is disclosed comprising an isolated antigen and a polynucleotide formulated into a nanoparticle or liposome. Furthermore, multivalent immunogenic compositions are disclosed comprising multiple univalent immunogenic compositions. Also disclosed, are methods of inducing protective or therapeutic immune responses in individuals comprising administering one or more univalent immunogenic compositions.
-
公开(公告)号:US20100298753A1
公开(公告)日:2010-11-25
申请号:US12847906
申请日:2010-07-30
申请人: HENRY J. SMITH , James R. Smith
发明人: HENRY J. SMITH , James R. Smith
IPC分类号: A61M1/36
CPC分类号: A61M1/3679 , A61M1/3693
摘要: This invention uses “targeted apheresis” to treat rheumatoid arthritis patients. “Targeted Apheresis” is a process whereby the RF and immune complexes responsible for causing the disease symptoms are selectively removed from the blood by passing the blood through a cartridge containing immobilized IgG. The RF and immune complexes are bound out and the cleaned blood is returned to the patient Removal of circulating RF and immune complexes will ameliorate the symptoms of rheumatoid arthritis.
-
4.
公开(公告)号:US20100247650A1
公开(公告)日:2010-09-30
申请号:US12415585
申请日:2009-03-31
申请人: Henry J. Smith , James R. Smith
发明人: Henry J. Smith , James R. Smith
IPC分类号: A61K9/10 , A61K39/395 , A61K38/18
CPC分类号: C07K16/2863 , A61K2039/505 , A61M1/3472 , A61M1/3489
摘要: This invention uses “targeted apheresis” to treat pregnant women who are at risk of developing eclampsia. “Targeted Apheresis” is a process whereby the sFlt-1 receptors responsible for causing the disease symptoms are selectively removed from the blood by passing the blood through a cartridge containing either immobilized PIGF, and/or through a cartridge containing immobilized anti-sFlt-1 antibody. The sFlt-1 receptor is bound out and the cleaned blood is returned to the patient Removal of circulating sFlt-1 receptors will diminish the risk of developing eclampsia during pregnancy.
摘要翻译: 本发明使用“靶向单采”来治疗处于发生子痫危险的孕妇。 “靶向单采”是指通过使血液通过含有固定化PIGF的药筒,和/或通过含有固定化的抗sFlt-1的药筒的药物,通过将血液通过含有固定化PIGF的药筒,选择性地从血液中除去引起疾病症状的sFlt-1受体 抗体。 sFlt-1受体被结合,清洁的血液返回给患者。循环sFlt-1受体的去除将降低怀孕期间发生子痫风险。
-
公开(公告)号:US10076600B2
公开(公告)日:2018-09-18
申请号:US14978910
申请日:2015-12-22
申请人: Henry J. Smith , James R. Smith
发明人: Henry J. Smith , James R. Smith
CPC分类号: A61M1/362 , A61M1/3486 , A61M1/3679 , B01D15/00 , B01D15/3804 , B01D15/3809
摘要: This invention uses “Targeted Apheresis” to treat patients with Rheumatoid Arthritis and other autoimmune and inflammatory disorders. “Targeted Apheresis” is a process whereby only the pathogenic and pro-inflammatory elements associated with the disease symptoms are simultaneously and selectively removed from the blood by passing the blood through an extracorporeal affinity device containing selective binding agents. Removal of these pathogenic and pro-inflammatory elements will ameliorate the symptoms of autoimmune disease and may prolong the period of disease remission.
-
公开(公告)号:US20100098698A1
公开(公告)日:2010-04-22
申请号:US12652561
申请日:2010-01-05
申请人: HENRY J. SMITH , James R. Smith
发明人: HENRY J. SMITH , James R. Smith
IPC分类号: A61K39/395
CPC分类号: A61M1/3679 , A61M1/3693
摘要: This invention uses “targeted apheresis” to treat rheumatoid arthritis patients. “Targeted Apheresis” is a process whereby the RF and immune complexes responsible for causing the disease symptoms are selectively removed from the blood by passing the blood through a cartridge containing immobilized IgG. The RF and immune complexes are bound out and the cleaned blood is returned to the patient Removal of circulating RF and immune complexes will ameliorate the symptoms of rheumatoid arthritis.
摘要翻译: 本发明使用“靶向单采”来治疗类风湿关节炎患者。 “靶向单采”是一种通过将血液通过含有固定化IgG的药筒从血液中选择性地除去引起疾病症状的RF和免疫复合物的过程。 RF和免疫复合物被结合,清洁的血液返回到患者。除去循环的RF和免疫复合物将改善类风湿性关节炎的症状。
-
公开(公告)号:US20120165261A1
公开(公告)日:2012-06-28
申请号:US13385642
申请日:2012-02-28
申请人: Scott M. Kee , Paul I. Cook , James R. Smith , Robert Kling , Scott A. Fowler , David Weber
发明人: Scott M. Kee , Paul I. Cook , James R. Smith , Robert Kling , Scott A. Fowler , David Weber
CPC分类号: A61K38/57 , A61K9/19 , B01D15/327 , B01D15/363 , C07K14/8125 , G01N30/461
摘要: A streamlined method for purifying alpha-1-antitrypsin (AAT) from an AAT-containing protein mixture, such as a Cohn fraction IV precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as a dithiol, which does not affect AAT. The destabilized proteins are then preferentially adsorbed on a solid protein-adsorbing material, without the addition of a salt as a precipitant. Separation of the solid adsorbent from the solution leaves a purified AAT solution that is directly suitable for chromatographic purification, without the need for extensive desalting as in prior art processes. A process incorporating this method, which provides pharmaceutical grade AAT in high yield on a commercial scale, is also described.
摘要翻译: 提供了从含有AAT的蛋白质混合物如Cohn馏分IV沉淀物中纯化α-1-抗胰蛋白酶(AAT)的流线型方法。 在本发明的方法中,污染蛋白质通过用不影响AAT的还原剂如二硫醇裂解二硫键而不稳定。 然后将不稳定的蛋白质优先吸附在固体蛋白质吸附材料上,而不加入作为沉淀剂的盐。 固体吸附剂与溶液的分离留下直接适用于色谱纯化的纯化AAT溶液,而不需像现有技术方法那样进行广泛的脱盐。 还描述了一种以商业规模提供高产量的药物级AAT的方法。
-
公开(公告)号:US06756091B1
公开(公告)日:2004-06-29
申请号:US09568616
申请日:2000-05-10
申请人: James R. Smith
发明人: James R. Smith
IPC分类号: B32B102
CPC分类号: B32B15/01 , B32B3/12 , B32B15/012 , B32B15/08 , B32B2323/043 , B32B2605/00 , F16F15/315 , Y10T74/2119 , Y10T74/2191 , Y10T428/1234 , Y10T428/13 , Y10T428/218 , Y10T428/24149
摘要: A lightweight flywheel containment composed of a combination of layers of various material which absorb the energy of a flywheel structural failure. The various layers of material act as a vacuum barrier, momentum spreader, energy absorber, and reaction plate. The flywheel containment structure has been experimentally demonstrated to contain carbon fiber fragments with a velocity of 1,000 m/s and has an aerial density of less than 6.5 g/square centimeters. The flywheel containment, may for example, be composed of an inner high toughness structural layer, and energy absorbing layer, and an outer support layer. Optionally, a layer of impedance matching material may be utilized intermediate the flywheel rotor and the inner high toughness layer.
摘要翻译: 轻质的飞轮安全壳,由吸收飞轮结构故障能量的各种材料的组合组成。 各种材料层用作真空屏障,动量扩张器,能量吸收器和反应板。 飞轮安全壳结构已被实验证明含有速度为1000米/秒的碳纤维碎片,其空气密度小于6.5克/平方厘米。 飞轮容纳物可以例如由内部高韧性结构层和能量吸收层和外部支撑层组成。 可选地,可以在飞轮转子和内部高韧性层之间使用阻抗匹配材料层。
-
公开(公告)号:US06372249B1
公开(公告)日:2002-04-16
申请号:US08327874
申请日:1994-10-24
IPC分类号: A61K9127
CPC分类号: A61K31/70 , A61K9/1272 , A61K38/00 , C07H21/00 , C07K14/4703 , C07K16/18 , C07K2319/00 , C12N15/113 , C12N2310/111 , C12N2310/322
摘要: The use of liposomal formulations, particularly formulations of positively charged and neutral lipids facilitates cellular uptake of SDI molecules. The transcription and/or expression of SDI-1-encoding nucleic acid molecules is facilitated by constructs that contain intervening untranslated regions.
摘要翻译: 使用脂质体制剂,特别是带正电荷和中性脂质的制剂促进SDI分子的细胞摄取。 编码SDI-1的核酸分子的转录和/或表达由包含中间非翻译区的构建体促进。
-
10.
公开(公告)号:US5473596A
公开(公告)日:1995-12-05
申请号:US164500
申请日:1993-12-09
CPC分类号: H04J3/14 , H04Q3/0075 , H04Q2213/13521 , H04Q2213/13545
摘要: A method of monitoring DS-0 alarm signals generated by telecommunication network elements, where the network elements include multiple network processing circuits connected to DS-1 facilities. The method comprises the steps of collecting the DS-0 alarm signals; cross-referencing the network elements and the network processing circuits to the DS-1 facilities; correlating the DS-1 facilities to customer circuit identification information; and routing the DS-0 alarm signals to a user location. The method allows a user to view customer outages in real time and also permits proactive observation and analysis of developing problems.
摘要翻译: 一种监测由电信网络元件生成的DS-0报警信号的方法,其中网络元件包括连接到DS-1设施的多个网络处理电路。 该方法包括收集DS-0报警信号的步骤; 将网络元素和网络处理电路交叉引用到DS-1设施; 将DS-1设备与客户电路识别信息相关联; 并将DS-0报警信号路由到用户位置。 该方法允许用户实时查看客户中断,并允许主动观察和分析开发中的问题。
-
-
-
-
-
-
-
-
-